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Background: The neurotrophins, which include nerve growth factor (NGF),
brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3), NT-4/5 and
NT-6, are a family of proteins that play fundamental roles in the differentiation,
survival and maintenance of peripheral and central neurons. Much research has
focused on the role of neurotrophins as target-derived, retrogradely transported
trophic molecules. Although there is recent evidence that BDNF and NT-3 can
be transported in an anterograde direction along peripheral and central axons,
there is as yet no conclusive evidence that these anterograde factors have
direct post-synaptic actions.
Results: We report that BDNF travels in an anterograde direction along the
optic nerve. The anterogradely transported BDNF had rapid effects on retinal
target neurons in the superior colliculus and lateral geniculate nucleus of the
brain. When endogenous BDNF within the developing superior colliculus was
neutralised, the rate of programmed neuronal death increased. Conversely,
provision of an afferent supply of BDNF prevented the degeneration of
geniculate neurons after removal of their cortical target.
Conclusions: BDNF released from retinal ganglion cells acts as a survival
factor for post-synaptic neurons in retinal target fields.
Background
Neurons require extracellular signals in order to survive
[1,2]. Target structures and afferent inputs represent the
main sources of trophic support [1,2]. Several molecules
that act as target-derived trophic factors have been identi-
fied. They bind to the nerve terminals of the responsive
neurons, are transported in a retrograde direction and
signal to the cell body [3–5]. Much less is known about the
molecular identity of anterograde trophic factors. Recently,
it has been demonstrated that the neurotrophins brain-
derived neurotrophic factor (BDNF) and neurotrophin-3
(NT-3) can be transported in an anterograde direction
along axons [6–10]. It has been suggested that this trans-
port may serve to regulate the survival, phenotype, synapse
formation, and dendritic growth of the target neurons
[6–10]. There is, however, no direct evidence that these
effects are caused by the release and post-synaptic action
of the anterogradely transported neurotrophin. 
Anterograde trophic influences have been described in
the visual system [11–13]. Second-order visual neurons in
the lateral geniculate nucleus (dLGN) and superior col-
liculus (SC) in the brain are known to require afferent
support from retinal ganglion cells (RGCs) during both
development and adulthood [11–13]. Endogenous BDNF
is a good candidate for this support because it is expressed
by RGCs [14,15] and its high-affinity receptor TrkB is
localised on neuronal cell bodies and dendrites in the
dLGN and SC [16]. Here, we report that BDNF is trans-
ported in an anterograde direction along the optic nerve
and released from RGC terminals to promote the survival
of post-synaptic neurons in retinal target fields.
Results
Anterograde transport of BDNF in the optic nerve
We first examined whether endogenous neurotrophins
are transported in an anterograde direction by RGCs in
adult rats. The optic nerve was ligated or crushed to inter-
rupt axonal transport, and the nerves were immunos-
tained with antibodies specific for BDNF or nerve growth
factor (NGF) 20 hours after the operation (Figure 1).
BDNF immunoreactivity was clearly detected in axons
proximal to where the nerve was crushed, indicating that
BDNF was transported in an anterograde direction towards
retinorecipient structures (Figure 1a). Retrograde accu-
mulation of BDNF was virtually undetectable (Figure 1a).
No NGF immunoreactive fibres could be detected on
either side of the ligation (Figure 1b). Anterograde trans-
port of endogenous BDNF was also detected in newborn
(P5) rats following an intracranial crush of the optic
nerve and visualisation of BDNF accumulation 20 hours
later. Numerous fibres on the proximal side, although
retracted, showed robust BDNF immunostaining (data
not shown).
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We next examined whether exogenous BDNF is also
transported by RGCs. Recombinant human BDNF (5 µg)
was injected intraocularly and a ligation placed in the
retro-orbital portion of the optic nerve in adult rats. After
3 hours, a time at which accumulation of endogenous
BDNF was still undetectable, many BDNF-positive fibres
could be observed proximal to the ligation (Figure 2).
Experiments performed in newborn rats yielded identical
results (see also [17]). These observations indicate that
exogenous BDNF injected into the vitreous humour is
rapidly taken up by retinal ganglion cells and transported
in an anterograde direction along the optic nerve.
Effects of BDNF on retinal target neurons
The demonstration of a specific anterograde transport of
BDNF prompted us to ask whether this factor exerts func-
tional effects on post-synaptic neurons in retinal target
fields. A short delay in the target response is essential to
establish a causal relationship between the anterograde
factor and its post-synaptic action. We therefore analysed
the expression of immediate-early genes (IEGs) that are
known to be rapidly induced by neurotrophins in respon-
sive cells [18]. BDNF was injected intraocularly and the
expression of the IEG products c-Fos and Zif268 was
examined in the SC and dLGN 5–7 hours after injection.
This time interval takes into account the time required
for fast axonal transport from RGCs to their targets
(~3–4 hours) [19] as well as the time necessary for maximal
IEG elevation in response to neurotrophin treatment
(2 hours). We found that the intraocular injection of
BDNF resulted in a clear induction of c-Fos and Zif268 in
the SC and dLGN innervated by the injected eye
(Figure 3a,b). Intravitreal injections of NGF failed to elicit
such a response (Figure 3a,b). The c-Fos-positive cells co-
expressed the neuronal marker NeuN, demonstrating that
the BDNF-induced IEG expression was restricted to
neurons (Figure 3c). IEG elevation in retinal targets was
dependent on axonal transport as co-injections of BDNF
and colchicine into the eye completely abolished IEG
staining (Figure 4a).
It might be argued that the intraocular injection of BDNF
stimulates RGCs to produce a secondary trophic signal
that, in turn, generates the target response. To rule out
this possibility, we used two distinct approaches: block of
BDNF signalling at the retinal level and neutralisation of
BDNF within the target by infusion of specific antibod-
ies. In a first set of experiments, we co-injected BDNF
and the tyrosine kinase inhibitor K252a into the adult
eye. As Trk receptors but not p75 receptors are present
on RGC bodies [20], K252a blocks all effects of BDNF
on RGCs. We found that K252a, when administered
intraocularly, failed to abolish the BDNF-induced IEG
expression in the SC and dLGN (Figure 4b). On the
other hand, we found that the stereotaxic administration
into the SC of antibodies that neutralise the biological
activity of BDNF resulted in a complete loss of the IEG
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Figure 1
Anterograde transport of endogenous BDNF in the adult rat optic
nerve. Immunohistochemical staining showed (a) accumulation of
BDNF, (b) but not NGF, in axons proximal to where the nerve was
crushed. Staining was performed 20 h after the operation. The
BDNF-labelled profiles show the typical morphology of fibre terminals
oriented towards the site of transport blockade (indicated by arrows).
The scale bar represents 200 µm.
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Figure 2
Anterograde transport of exogenous BDNF in the adult rat.
Longitudinal section through the optic nerve, showing build-up of
exogenous BDNF in axons proximal to a ligation, 3 h following
intraocular BDNF injection. The ligation site is indicated by an arrow.
The scale bar represents 200 µm.
response (Figure 5a,b). Two distinct anti-BDNF antibod-
ies (RAB from Amgen and chicken anti-BDNF antibody
from Promega) whose neutralising activity has been
demonstrated in vitro and in vivo [21–23] were used and
gave identical results. Injection of a control anti-horserad-
ish peroxidase (HRP) antibody (Sigma) into the SC was
unable to block the BDNF-induced IEG upregulation,
thus confirming the specificity of the blocking effect (data
not shown). These experiments were replicated in neonates
with identical results. The function-blocking anti-BDNF
antibodies were injected bilaterally into the SC of P5 rats
and BDNF was administered intraocularly. No IEG stain-
ing could be seen in the colliculi but a normal labelling was
found in the geniculate (data not shown).
Endogenous BDNF reduces natural cell death in the
superior colliculus
Our data demonstrate that BDNF is transported in an
anterograde direction and released by RGC terminals to
act directly on the post-synaptic neurons. We next tested
whether regulating the availability of BDNF affects neu-
ronal survival in retinal target fields. The SC of the rat
undergoes a period of naturally occurring cell death that
peaks between P5 and P8 [12]. We neutralised endoge-
nous BDNF in the SC of P5 rats by injecting the BDNF-
neutralising antibody RAB. Rabbit immunoglobulin G
(IgG) was injected as a control and cell death was evalu-
ated by stereological techniques 3 hours following the
antibody infusions. The mean density of pyknotic cells
was increased twofold in animals injected with the anti-
BDNF antibody, compared with controls (t-test, p < 0.05;
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Figure 3
Anterogradely transported BDNF modulates gene expression in retinal
target structures. Adult rats received intraocular injections of BDNF
(40 µg) in one eye and NGF (40 µg) in the other eye. The expression
of the IEG products c-Fos and Zif268 was analysed in the SC and
dLGN, 5 h after injection. (a) Coronal section through the SC
immunostained with anti-c-Fos antibodies. A clear band of
immunoreactive cells was visible within the SC contralateral to the
BDNF-injected eye (right). The SC contralateral to the eye injected
with NGF was not stained (left). (b) Coronal section through the dLGN
immunostained for c-Fos. Strong c-Fos induction was restricted to the
dLGN subfields receiving input from the BDNF-injected eye. In the
dLGN ipsilateral to the BDNF injection (left), a narrow patch of stained
cells was observed that matched the uncrossed retinal terminal field.
The entire dLGN contralateral to the BDNF injection was stained
(right) except for the small area innervated by the NGF-treated eye.
(c) Coronal sections through the SC contralateral to the BDNF-
injected eye were double-stained with anti-c-Fos (green) and anti-
NeuN (red) antibodies. Double staining revealed that the c-Fos-positive
nuclei were also NeuN immunoreactive. The scale bar represents
600 µm in (a), 300 µm in (b) and 15 µm in (c).
   Current Biology
(a)
(b)
(c)
Figure 4
BDNF-induced IEG expression requires axonal transport but not Trk
signalling within the retina. Coronal sections through the SC,
immunostained for c-Fos. (a) This animal received BDNF in one eye
and BDNF plus colchicine in the other eye, and was killed 7 h later.
Strong induction of c-Fos expression was observed along the
retinorecipient margin of the SC contralateral to the BDNF-injected
eye (right). The SC contralateral to the eye injected with BDNF plus
colchicine was not stained (left). (b) This animal received BDNF plus
K252a in one eye and K252a alone in the other eye, and was killed
7 h later. The SC contralateral to the eye injected with BDNF
plus K252a showed strong c-Fos staining (right), whereas K252a
alone had no effect (left). The scale bar represents 350 µm in (a)
and 400 µm in (b).
Figure 6). This demonstrates a role for endogenous BDNF
in promoting the survival of SC neurons.
Anterograde supply of BDNF rescues axotomised
geniculate neurons
We next determined whether an anterograde supply of
exogenous BDNF could be exploited to prevent the death
of dLGN neurons after ablation of the visual cortex.
Neonatal rats were selected as an experimental model
because of the rapidity of the death process at this age.
Indeed, previous studies have shown that removal of the
visual cortex in newborn rats leads to the death of all
dLGN cells within 96 hours, with a peak in pyknosis at
48 hours after the lesion [24,25]. Monocular injections of
BDNF, or saline as control, was performed either 24 or
36 hours after ablation of the visual cortex, and cell death
was evaluated at 48 hours in the dLGN ipsilateral to the
lesion. For each animal, we measured the level of pykno-
sis in the two eye-specific subfields of the lesioned dLGN
(Figure 7). The quantitative analysis showed that intraoc-
ular BDNF was remarkably effective in preventing dLGN
cell death. Indeed, the density of pyknotic cells was
reduced to 50% in the treated patch following BDNF
administration at either 24 or 36 hours after ablation of the
visual cortex (Figure 8a). In contrast, no difference
between treatments could be detected in the untreated
dLGN patch (analysis of variance, p = 0.72). This ensures
that the effects of cortical injury are comparable in all
animal groups. The BDNF rescue effect was dependent
on axonal transport from the retina, as it was completely
blocked by intraocular administration of colchicine, but
not on BDNF signalling within the retina, as shown by
blocking the BDNF transduction cascade at the retinal
level with K252a (Figure 8b).
Discussion
Anterograde transport of BDNF
We have demonstrated for the first time that the endoge-
nous BDNF synthesised by RGCs is transported in an
anterograde direction along the optic nerve in both devel-
oping and adult rats. On the other hand, retrograde trans-
port of endogenous BDNF was not detectable. Thus,
despite the known retrograde effects of BDNF on RGCs
[20,26], the physiological trafficking of BDNF was mainly
in the anterograde direction in the optic nerve. BDNF-
immunoreactive terminals have been demonstrated in both
the dLGN and SC [27], suggesting that BDNF, transported
in the anterograde direction, is stored in nerve terminals
within the RGC innervation targets where it could be
released through activity-dependent mechanisms [28].
We have also demonstrated the ability of RGCs to take
up, transport and release exogenous BDNF injected into
the vitreous humour. It is still unresolved whether the
endogenous and exogenous neurotrophins accumulate in
the same cellular compartments and share the same mech-
anisms of transport.
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Figure 5
(a,b) Anti-BDNF antibodies block the upregulation of IEG expression
that is induced in the SC by intraocular injection of BDNF. Adult rats
received unilateral stereotaxic injections of function-blocking anti-
BDNF antibodies into the SC. BDNF was administered in both eyes.
(a) Coronal section through the brainstem of an adult rat, immunostained
to visualise the extent of diffusion of the injected chicken anti-BDNF
antibodies. Only the SC on the side ipsilateral to the injection was
stained. (b) Staining of c-Fos in a coronal section through the SC
adjacent to that shown in (a). Labelled cells were evident in the
uninjected SC (right), but absent in the side infused with anti-BDNF
antibody (left). The scale bar represents 1.5 mm in (a) and 500 µm in (b).
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Infusion of anti-BDNF antibodies increases the rate of developmental
death in the SC. The graph shows the mean density of pyknotic nuclei
in the SC of animals injected with control rabbit IgG (n = 4) or RAB
(n = 5). The error bars indicate SEM.
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Post-synaptic effects of anterograde BDNF
Previous studies have shown convincingly anterograde
transport of BDNF and NT-3 in selected peripheral and
central pathways [6–9]. The anterogradely transported
neurotrophins have been proposed to play a role in neu-
ronal survival, phenotype regulation, synaptic plasticity
and also as conventional neurotransmitters [29]. For
example, transport of both exogenous and endogenous
NT-3 has been demonstrated in the retino-tectal pathway
of chick embryos [6,7]. A paper by Altar et al. [8] has
reported transport of endogenous BDNF from cortical
afferents to striatal neurons in the rat. Deletion of the
BDNF gene reduces the number of parvalbumin-express-
ing striatal neurons, consistent with a post-synaptic role for
the anterogradely transported BDNF [8]. Fawcett et al. [9]
found localisation of BDNF in noradrenergic terminals of
the adult brain. Using transgenic mice that overexpress
BDNF in noradrenergic neurons, they demonstrated
major effects of BDNF over-expression in noradrenergic
target regions, namely a reduced cortical thickness and an
increased survival of axotomised facial motoneurons [9].
In all of these studies, however, it was difficult to establish
whether the observed post-synaptic effects are due to the
direct action of the anterogradely transported neu-
rotrophin. Here, using the expression of the c-Fos and
Zif268 gene products as a marker, we have provided com-
pelling evidence that the exogenous, anterogradely trans-
ported BDNF is released from RGC terminals and acts
directly on the target neurons.
Physiological role of the anterogradely transported BDNF
It has long been known that second-order visual neurons
in the SC and dLGN depend on their afferents from the
retina for survival. Blockade of axonal transport or spike
activity in the eye leads to neuronal death in retinal targets
[11–13]. These experiments point to the existence of
some anterograde trophic signal(s) for retinal target neurons
that are released in an activity-dependent manner. Our
data demonstrate that BDNF is one of these factors.
Indeed, increasing or reducing the availability of BDNF
regulates neuronal survival in retinal target fields. First,
we have shown that infusion of function-blocking anti-
BDNF antibodies into the developing SC increases the
number of cells undergoing programmed cell death. This
demonstrates that BDNF is an endogenous survival factor
for SC neurons. To our knowledge, this is the first demon-
stration of the effects of endogenous BDNF on the devel-
opmental death of one population of central neurons. The
effects of the anti-BDNF antibody were already apparent
3 hours after infusion. A similarly rapid increase in the rate
of cell death has been observed following enucleation or
intravitreal injection of tetrodotoxin (TTX) [12], suggest-
ing that the endogenous BDNF necessary for survival is
derived from retinal sources in an activity-dependent way.
Nevertheless, as the antibodies remove all BDNF in the
tectum, the possibility cannot be excluded that at least
some of the BDNF is provided to the SC cells by
paracrine or autocrine pathways, or by an additional, so far
unidentified, afferent source.
Second, provision of an anterograde supply of BDNF was
able to prevent the death of geniculate neurons following
cortical lesions. A specific retrograde action of cortically
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Figure 7
Coronal section through the dLGN of a P9 rat that received a unilateral
occipital cortex lesion 48 h earlier. Retinal projections were labelled
with intravitreal HRP (black) and the section counterstained with cresyl
violet. Note the clear segregation of eye-specific inputs within the
dLGN and the shrunken dLGN on the side ipsilateral to the lesion.
Inset, many pyknotic cells (arrowheads) were present in the lesioned
dLGN 48 h after surgery. The scale bar represents 100 µm (15 µm for
the inset).
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Figure 8
Application of BDNF into the eye prevents the degeneration of thalamic
neurons following injury. (a) Average density of pyknotic nuclei in the
dLGN subfield receiving input from the eye injected with saline or
BDNF. Stereological counting of pyknotic cells using the optical
fractionator method (see Materials and methods) revealed a significant
decrease in the density of pyknotic cells following BDNF treatment at
either 24 or 36 h post-lesion compared with the saline control (analysis
of variance; post hoc Tukey test, p < 0.05 for both BDNF time points).
For each histogram, n = 7–15 rats. (b) Coinjection of colchicine (col),
but not of K252a, blocks the BDNF effect completely (analysis of
variance; post hoc Tukey test: BDNF versus BDNF plus colchicine,
p < 0.05; BDNF versus BDNF plus K252a, p > 0.05). For each
histogram, n = 3 or 4 rats. The error bars indicate SEM.
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derived NT-4 has been shown in the ferret dLGN by
Riddle et al. [30]. Thus, geniculate neurons appear to
require two different TrkB ligands from different sources,
anterograde BDNF from the retina and retrograde NT-4
from the cortex.
Supply of trophic factor to the thalamus through
intraocular injections
The BDNF rescue effect on the geniculate cells can also
have important clinical implications. A secondary, massive
loss of thalamic neurons has been described in both
animal models and man following cortical traumatic insults
and cerebral ischemia [31–33]. This thalamic damage is a
serious obstacle for pathway rewiring and functional recov-
ery [34]. We have shown that BDNF delivery within the
eye is a very effective strategy for promoting geniculate
survival after cortical lesions. The clinical application of
neurotrophins has been limited by the fact that these
factors do not cross the blood–brain barrier and need to be
administered directly into the brain parenchyma [35]. Our
data demonstrate the feasibility of supplying functionally
significant amounts of BDNF to the injured geniculate
through a minimally invasive route through the eye.
Materials and methods
Animal treatment
The procedures used in this study were approved by the Italian Ministry
of Public Health. For analysis of the anterograde transport of endoge-
nous neurotrophins, 10 Long-Evans adult rats were deeply anes-
thetised with avertin (1 ml/100g body weight) and the optic nerve was
either ligated or crushed mechanically with thin surgical forceps. In
three rats, a double ligation was performed. Three P5 rats were also
used. They were anesthetised by hypothermia and the optic nerve was
crushed intracranially to visualise accumulation of endogenous neu-
rotrophins. All animals were killed 20 h after surgery.
Intraocular injections of neurotrophins were performed with a glass
micropipette connected to a microinjector. For the study of transport of
exogenous BDNF, the optic nerve was ligated and the animals (n = 3)
killed 3 h after the intraocular BDNF injection. For the study of IEG
expression, we injected 28 adult and 16 newborn (P5–P7) rats.
Animals received a total of 5–40 µg 2.5S mouse NGF or 5–40 µg
recombinant human BDNF and were killed 5–7 h later. In co-injection
experiments, 1 µg of the axonal transport blocker colchicine or 0.7 µg
of the Trk phosphorylation blocker K252a were injected intraocularly
30–60 min before the BDNF administration. The dose of colchicine
used was verified to block completely fast anterograde transport from
the retina. The K252a batch used was shown to be effective in block-
ing Trk phosphorylation of BDNF-treated cortical neurons in culture. 
Stereotaxic injections of anti-BDNF antibodies (RAB from Amgen,
0.3 mg/ml; chicken anti-BDNF antibody from Promega, 0.5 mg/ml) and
control anti-HRP antibodies (mouse monoclonal, Sigma P6-38) were
performed unilaterally into the SC of adult rats (volume injected, 2 µl);
5 h later, the rats were given bilateral intraocular injections of BDNF
(40 µg). Animals were killed 5 h following the BDNF administration and
the brains processed for c-Fos and Zif268 immunostaining. An identi-
cal protocol was followed in the P5 rats.
Immunohistochemistry
Animals were anesthetised with chloral hydrate and perfused transcardially
with PBS followed by fixative containing 4% paraformaldehyde in 0.1 M
phosphate buffer, pH 7.4 (for BDNF, c-Fos and Zif268 immunostaining) or
2% paraformaldehyde + 0.2% parabenzoquinone in 0.075 M phos-
phate buffer, pH 7.4 (for NGF immunostaining). Optic nerves and brains
were dissected, rinsed in buffer and cryoprotected in 30% sucrose.
Longitudinal optic nerve sections (12 µm thick) and coronal brain sec-
tions (40 µm thick) were obtained by using a cryostat and a sliding
microtome, respectively. After a blocking step, sections were incubated
overnight in rabbit polyclonal antibodies diluted as follows: anti-NGF
antibody, 0.75 µg/ml (a kind gift of J.M. Conner); anti-BDNF antibody,
1 µg/ml (affinity-purified polyclonal antibody RAB, a kind gift of Q. Yan);
anti-c-Fos antibody 1:10,000 (Oncogene Sciences); anti-Zif268 anti-
bodies 1:1,000 (Santa Cruz Biotechnology). The anti-NGF and anti-
BDNF antibodies have been characterised in previous studies
[21,27,36]. Bound antibodies were detected by incubating sections
with biotinylated goat anti-rabbit IgG (1:200, Vector Labs) followed by
fluorescein-conjugated avidin (1:300, Vector). Selected c-Fos-stained
brain sections were reacted with mouse monoclonal anti-NeuN anti-
body (1:500, Chemicon) followed by Alexa 568-conjugated anti-mouse
IgG (1:400, Molecular Probes).
Evaluation of natural cell death in the SC
P5 rats were injected into the SC with RAB or control rabbit IgG (2 µl
of a 0.3 µg/µl solution) under ether anesthesia. They were perfused 3 h
later with 4% paraformaldehyde in 0.1 M phosphate buffer, pH 7.4.
Coronal sections through the SC were cut with a freezing microtome
and stained with cresyl violet.
The extent of diffusion of the injected antibodies was checked by stain-
ing selected coronal sections with anti-rabbit IgG biotinylated sec-
ondary antibodies, followed by ABC kit (Vector) and nickel-enhanced
diaminobenzidine (DAB) reaction. Animals with limited antibody pene-
tration were discarded. For the analysis of natural cell death, three to
four coronal sections were selected for each injected SC according to
a systematic random scheme [37,38]. Pyknotic nuclei were counted in
three-dimensional sampling fields (80 × 80 × 10 µm) equally spaced
from medial to lateral in the superficial layers of the SC (Stereo Investi-
gator, Microbrightfield). An average of 100 fields were counted in each
injected SC. To rule out that the differences in the density of pyknotic
cells may result from unequal tissue shrinkage, we also estimated the
density of living cells in each SC. For this analysis, three equally
spaced sampling fields were counted in each coronal section (3–6
sections per animal). We found that the mean density of living cells
was virtually identical (t-test, p = 0.9) in the rats treated with anti-BDNF
antibody and control rats.
Lesion experiments
Unilateral lesions of the visual cortex were made by aspiration in a total
of 48 P7 rats under ether anesthesia. Monocular injections of BDNF
(40 µg) were performed at 24 h (n = 7) or 36 h (n = 8) post-lesion.
Fifteen rats received injections of saline solution and served as con-
trols; 1 h after BDNF or saline injection, all animals received an intravit-
real injection of 3 µl 30% HRP to label the retino-geniculate
projections. Another group of 12 rats with visual cortex lesion was
used to determine whether the co-administration of either colchicine or
K252a prevents the BDNF effects. These animals were injected intrav-
itreally with HRP at 20 h post-lesion. BDNF, BDNF plus colchicine, or
BDNF plus K252a were administered 36 h post-lesion. All rats were
perfused through the heart with a mixture of 1% paraformaldehyde and
1.25% glutaraldehyde in 0.1 M phosphate buffer (pH 7.2) 48 h after
ablation of the visual cortex. Coronal sections, 50 µm thick, were cut on
a sliding microtome and collected in serial order through the entire thal-
amus and SC. HRP signal was revealed using the tetramethylbenzidine
(TMB) procedure and the sections were then counterstained with
cresyl violet for cell somata. 
Quantitative analysis of pyknosis in the dLGN
The quantitative analysis of pyknosis in the dLGN employed the princi-
ples of a modified version of the ‘dissector’ method called optical frac-
tionator. The optical fractionator is a combination of performing counting
with the optical dissector with fractionator sampling [37,38]. Analysis
1160 Current Biology Vol 10 No 19
was performed in a blind coded fashion using the Stereo Investigator
(Microbrightfield) software and a Zeiss microscope. Six to eight coronal
sections through the middle of the dLGN in the rostrocaudal axis were
randomly selected. Boundaries of the two eye-specific subfields (identi-
fied by HRP histochemistry) within the lesioned dLGN were drawn for
each section at 20× magnification. For each subfield, pyknotic nuclei
were counted at 100× magnification in three-dimensional counting
boxes (40 × 40 × 12 µm) selected in a systematically random manner.
The mean number of pyknotic cells per counting box was then deter-
mined and the density of pyknotic cells per mm3 of tissue derived for
each dLGN subfield. This method allows comparison of the level of
death in the treated and untreated portion of the lesioned dLGN so that
the untreated patch provides an internal control.
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